Oliver Engert Buys 2,458 Shares of Enovis (NYSE:ENOV) Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 2,458 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were purchased at an average price of $20.32 per share, for a total transaction of $49,946.56. Following the completion of the purchase, the insider directly owned 56,098 shares of the company’s stock, valued at approximately $1,139,911.36. This trade represents a 4.58% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Oliver Engert also recently made the following trade(s):

• On Thursday, September 3rd, Oliver Engert purchased 5,140 shares of Enovis stock. The shares were acquired at an average cost of $19.46 per share, with a total value of $100,024.40.
• On Monday, June 15th, Oliver Engert bought 1,000 shares of Enovis stock. The shares were acquired at an average price of $20.92 per share, with a total value of $20,920.00.
• On Thursday, June 11th, Oliver Engert bought 1,200 shares of Enovis stock. The stock was bought at an average price of $21.62 per share, with a total value of $25,944.00.
• On Wednesday, June 10th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was bought at an average price of $23.00 per share, with a total value of $23,000.00.

Enovis Price Performance

Shares of NYSE ENOV opened at $18.58 on Friday. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. The stock has a market cap of $1.07 billion, a P/E ratio of -0.96 and a beta of 1.31. The stock has a 50 day moving average of $25.50 and a two-hundred day moving average of $24.20. Enovis Corporation has a twelve month low of $18.52 and a twelve month high of $34.28.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. During the same quarter in the prior year, the firm earned $0.79 EPS. Enovis’s revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ENOV has been the topic of several recent analyst reports. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. BTIG Research lowered their price target on shares of Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday. Citizens Jmp dropped their price objective on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research note on Wednesday. Wall Street Zen downgraded Enovis from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Canaccord Genuity Group reduced their target price on Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, August 17th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.38.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENOV. Arax Advisory Partners acquired a new stake in Enovis during the fourth quarter worth about $29,000. Allworth Financial LP acquired a new position in shares of Enovis in the 2nd quarter valued at about $36,000. EverSource Wealth Advisors LLC grew its holdings in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. Public Employees Retirement System of Ohio purchased a new stake in shares of Enovis during the 2nd quarter worth about $48,000. Finally, Danske Bank A S acquired a new stake in Enovis during the 3rd quarter worth approximately $64,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis News Summary

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
• Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
• Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
• Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
• Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
• Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.